MiMedx Group, Inc. (MDXG) Income Statement
MDXG 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsMDXG revenue and net income
Where MDXG's revenue goes
2025Each bar shows an amount and its share of revenue. MDXG kept 11.6% of revenue as net income.
MDXG profit margins
MDXG growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +20.0% | +16.1% | +11.0% | +8.4% |
| Gross profit | +19.7% | +16.3% | +10.6% | +7.5% |
| Operating income | +8.5% | — | — | +10.1% |
| Net income | +14.5% | — | — | +5.1% |
| EPS (diluted) | +51.7% | — | +37.4% | +5.0% |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
MDXG quarterly EPS vs estimates
MiMedx beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: October 28, 2026.
MDXG income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $418.6M | $348.9M | $321.5M | $267.8M | $242.0M | $248.2M | $359.1M | $359.1M | $321.1M | $245.0M |
| Cost of revenue | $73.0M | $60.1M | $54.6M | $48.3M | $39.6M | $39.3M | $36.4M | $36.4M | $35.2M | $32.4M |
| Gross profit | $345.6M | $288.8M | $266.8M | $219.5M | $202.4M | $208.9M | $322.7M | $322.7M | $285.9M | $212.6M |
| Research & development | $15.1M | $12.3M | $12.7M | $12.7M | $9.9M | $11.7M | $15.8M | $15.8M | $17.9M | $14.3M |
| Sales, general & admin | $266.2M | $225.1M | $206.7M | $208.8M | $198.4M | $181.0M | $252.6M | $252.6M | $216.0M | $170.1M |
| Total operating expenses | $281.3M | $229.9M | $229.7M | $234.3M | $209.4M | $254.3M | $326.6M | $326.6M | $239.7M | $191.4M |
| Operating income | $63.9M | $58.9M | $37.1M | −$14.7M | −$7.1M | −$45.4M | −$3.9M | −$3.9M | $46.2M | $884,000 |
| Interest expense | $1.8M | $1.0M | $6.5M | $5.0M | $5.0M | $7.9M | $0 | $0 | $87,000 | $339,000 |
| Income before taxes | $66.3M | $57.3M | $30.6M | −$19.7M | −$12.1M | −$61.5M | −$3.4M | −$3.4M | $45.1M | $545,000 |
| Income taxes | $17.7M | $15.3M | −$36.8M | $206,000 | $247,000 | −$12.3M | $26.6M | $26.6M | −$19.6M | $6.1M |
| Net income | $48.6M | $42.4M | $67.4M | −$30.2M | −$12.3M | −$49.3M | −$30.0M | −$30.0M | $64.7M | $12.0M |
| EBITDA | $82.9M | $65.4M | $40.5M | −$10.7M | −$1.9M | −$37.5M | $17.6M | $3.0M | $52.6M | $8.9M |
| EPS (diluted) | $0.44 | $0.29 | $0.34 | −$0.25 | −$0.14 | $0.09 | $0.21 | −$0.35 | $0.32 | $0.22 |
| Gross margin | 82.6% | 82.8% | 83.0% | 82.0% | 83.6% | 84.2% | 89.9% | 89.9% | 89.0% | 86.8% |
| Operating margin | 15.3% | 16.9% | 11.5% | −5.5% | −2.9% | −18.3% | −1.1% | −1.1% | 14.4% | 0.4% |
| Net margin | 11.6% | 12.2% | 21.0% | −11.3% | −5.1% | −19.9% | −8.3% | −8.3% | 20.2% | 4.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $64.4M | $59.0M | $118.1M | $113.7M | $98.6M | $88.2M | $92.9M | $84.1M | $87.2M | $84.7M | $86.8M | $81.7M |
| Cost of revenue | $20.0M | $17.4M | $19.1M | $18.7M | $18.7M | $16.6M | $16.9M | $15.3M | $15.0M | $13.2M | $13.8M | $14.8M |
| Gross profit | $44.4M | $41.6M | $99.0M | $95.0M | $79.9M | $71.6M | $76.0M | $68.7M | $72.2M | $71.5M | $73.0M | $66.9M |
| Research & development | $2.8M | $4.1M | $4.8M | $3.7M | $3.3M | $3.3M | $3.6M | $2.9M | $3.0M | $2.8M | $2.4M | $3.1M |
| Sales, general & admin | $59.8M | $53.2M | $73.1M | $69.0M | $64.2M | $60.0M | $61.0M | $53.5M | $55.4M | $55.1M | $54.4M | $52.6M |
| Total operating expenses | $62.8M | $57.7M | $77.8M | $72.8M | $67.6M | $63.4M | $64.9M | $57.6M | $48.9M | $58.5M | $57.5M | $55.8M |
| Operating income | −$18.5M | −$16.0M | $21.1M | $22.2M | $12.4M | $8.3M | $11.1M | $11.2M | $23.4M | $13.2M | $15.5M | $11.1M |
| Interest income | — | $1.3M | — | $785,000 | — | $984,000 | — | $278,000 | — | — | — | — |
| Interest expense | — | $402,000 | $405,000 | $785,000 | $475,000 | $478,000 | $2.5M | $278,000 | $3,000 | $1.7M | $1.6M | $1.7M |
| Income before taxes | −$17.8M | −$15.3M | $21.8M | $22.8M | $13.0M | $8.6M | $11.2M | $11.4M | $23.2M | $11.4M | $13.9M | $9.4M |
| Income taxes | −$2.9M | −$4.5M | $6.6M | $6.1M | $3.4M | $1.6M | $3.8M | $3.5M | $5.6M | $2.3M | −$37.4M | $591,000 |
| Net income | −$14.8M | −$10.9M | $15.2M | $16.7M | $9.6M | $7.0M | $7.4M | $8.1M | $17.6M | $9.3M | $53.5M | $8.5M |
| EBITDA | −$16.9M | −$13.7M | $25.4M | $28.9M | $16.6M | $12.3M | $14.1M | $12.6M | $24.4M | $14.0M | $16.3M | $12.0M |
| EPS (diluted) | −$0.05 | −$0.05 | $0.14 | $0.15 | $0.10 | $0.05 | $0.07 | $0.07 | $0.08 | $0.07 | $0.32 | $0.05 |
| Gross margin | 69.0% | 70.6% | 83.9% | 83.5% | 81.1% | 81.2% | 81.8% | 81.8% | 82.7% | 84.4% | 84.1% | 81.9% |
| Operating margin | −28.7% | −27.2% | 17.8% | 19.5% | 12.5% | 9.4% | 11.9% | 13.3% | 26.9% | 15.6% | 17.8% | 13.6% |
| Net margin | −23.1% | −18.4% | 12.9% | 14.7% | 9.8% | 8.0% | 8.0% | 9.6% | 20.2% | 10.9% | 61.6% | 10.4% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in MDXG's financial statements (latest annual report filed February 25, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
MDXG financial results
In fiscal year 2025 (ended December 31, 2025), MiMedx reported revenue of $418.6 million, up 20.0% from the year before. It had net income of $48.6 million (up 14.5%), a net profit margin of 11.6%. Diluted earnings per share came to $0.44. Over five years revenue grew at an average rate of 11.0% a year.
See the MDXG stock overview for the latest quote and news, or the MDXG chart for price history and technical indicators.
MDXG income statement FAQ
What is MiMedx's annual revenue?
MiMedx reported total revenue of $418.6 million for fiscal year 2025, which ended on December 31, 2025. That was up 20.0% from $348.9 million the previous year.
Is MiMedx profitable?
Yes. MiMedx reported net income of $48.6 million in fiscal 2025, a net profit margin of 11.6%; its operating margin was 15.3%.
What is MiMedx's gross margin?
MiMedx's gross margin was 82.6% in fiscal 2025: for every $100 of revenue, MiMedx kept $83 after the direct cost of its products and services.
How much does MiMedx spend on research and development?
MiMedx spent $15.1 million on research and development in fiscal 2025, 3.6% of revenue.
How fast is MiMedx growing?
Revenue grew 11.0% a year on average over the last five fiscal years, from $248.2 million to $418.6 million.
What are MiMedx's earnings per share?
MiMedx earned $0.44 per diluted share in fiscal 2025, compared with $0.29 a year earlier.
When will MiMedx report its next earnings?
MiMedx is expected to report results for the quarter ending September 30, 2026 on October 28, 2026 after the market closes.
When does MiMedx's fiscal year end?
MiMedx's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 25, 2026.